Arcadia Biosciences (RKDA) Common Equity (2014 - 2025)

Arcadia Biosciences' Common Equity history runs 12 years deep, the most recent figure standing at $4.1 million for Q4 2025.

• Quarterly Common Equity fell 33.47% year-over-year to $4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (down 33.47% YoY) and the FY2025 annual result came in at $4.1 million, down 33.47% from the prior year.
• Common Equity was $4.1 million for Q4 2025 at Arcadia Biosciences, down from $5.4 million in the prior quarter.
• Across five years, Common Equity topped out at $45.7 million in Q1 2021 and bottomed at $4.1 million in Q4 2025.
• A 5-year average of $19.3 million and a median of $16.0 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity jumped 273.91% — and 2025, when it tumbled 60.81%.
• Arcadia Biosciences' Common Equity stood at $31.2 million in 2021, then plunged by 33.0% to $20.9 million in 2022, then slumped by 39.22% to $12.7 million in 2023, then plunged by 51.01% to $6.2 million in 2024, then slumped by 33.47% to $4.1 million in 2025.
• Business Quant data shows RKDA's Common Equity at $4.1 million in Q4 2025, $5.4 million in Q3 2025, and $4.5 million in Q2 2025.